Issues related to clinical diagnostic laboratory services; H.R. 2369 The Verifying Leading-edge IVCT Development Act, S. 2333 Pandemic and All-Hazards Preparedness and Response Act, issues related to public health emergency preparedness.
S. 1000/H.R. 2377 Saving Access to Laboratory Services (SALSA); H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Duration: January 1, 2018
to
present
General Issues: Health Issues , Medicare/Medicaid , Medical/Disease Research/Clinical Labs , Budget/Appropriations , Pharmacy , Chemicals/Chemical Industry
Spending: about $1,120,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2018: U.S. Senate, House of Representatives, Centers For Medicare and Medicaid Services (CMS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Lisa Layman SPA, Stabenow; SPA, Sen. Graham; LA, Sen. Bryan, LA, Sen. Chafee; CBO, PA
SPA, Sen Stabenow (2005-2007); SPA, Sen Graham (2001 - 2004); LA, Sen Bryan (2000); LA, Sen Chafee (1997 - 1999); CBO, PA (1992 - 1996)
Lisa Layman
SPA, Sen Stabenow (2005-2007); SPA, Sen Graham (2001 - 2004); LA, Sen Bryan (2000); LA, Sen Chafee (1997 - 1999); CBO, PA (1992 - 1996)
Martin Corry n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Hooper, Lundy & Bookman, P.C. lobbied for Roche Diagnostics Corporation , earning $30,000. The report was filed on April 19.
Original Filing: 301566025.xml
Lobbying Issues
Issues related to clinical diagnostic laboratory services; H.R. 2369 The Verifying Leading-edge IVCT Development Act, S. 2333 Pandemic and All-Hazards Preparedness and Response Act, issues related to public health emergency preparedness.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 1000/H.R. 2377 Saving Access to Laboratory Services (SALSA); H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, Hooper, Lundy & Bookman, P.C. lobbied for Roche Diagnostics Corporation , earning $30,000. The report was filed on Jan. 18.
Original Filing: 301528447.xml
Lobbying Issues
Issues related to clinical diagnostic laboratory services; S. 2333 Pandemic and All-Hazards Preparedness and Response Act, issues related to public health emergency preparedness; HR 4366-Fiscal Year 2024 Minibus Appropriations relating to laboratory developed tests.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 1000/H.R. 2377 Saving Access to Laboratory Services (SALSA); H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, Hooper, Lundy & Bookman, P.C. lobbied for Roche Diagnostics Corporation , earning $30,000. The report was filed on Oct. 19, 2023.
Original Filing: 301507637.xml
Lobbying Issues
Issues related to clinical diagnostic laboratory services; Issues related to public health emergency preparedness.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 1000/H.R. 2377 Saving Access to Laboratory Services (SALSA).
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, Hooper, Lundy & Bookman, P.C. lobbied for Roche Diagnostics Corporation , earning $40,000. The report was filed on July 20, 2023.
Original Filing: 301488988.xml
Lobbying Issues
Issues related to clinical diagnostic laboratory services; Issues related to public health emergency preparedness; H.R. 2369 The Verifying Leading-edge IVCT Development Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 2369 The Verifying Leading-edge IVCT Development Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
S.1000 / H.R. 1835 Saving Access to Laboratory Services Act (SALSA).
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, Hooper, Lundy & Bookman, P.C. lobbied for Roche Diagnostics Corporation , earning $50,000. The report was filed on April 20, 2023.
Original Filing: 301461278.xml
Lobbying Issues
Issues related to clinical diagnostic laboratory services; issues related to public health emergency preparedness; H.R. 2369 The Verifying Leading-edge IVCT Development Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 2369 The Verifying Leading-edge IVCT Development Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
S.1000 / HR 1835 Saving Access to Laboratory Services Act (SALSA).
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, Hooper, Lundy & Bookman, P.C. lobbied for Roche Diagnostics Corporation , earning $50,000. The report was filed on Jan. 20, 2023.
Original Filing: 301442730.xml
Lobbying Issues
H.R. 4128/S. 2209, The Verifying Leading-edge IVCT Development Act of 2021.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Disease Research/Clinical Labs
Lobbying Issues
S.4449 / HR 8188 Saving Access to Laboratory Services Act (SALSA).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Public Law 117-328, the Consolidated Appropriations Act, 2023, relating to Medicare payment rates for clinical diagnostic laboratory services (H.R. 8188/S. 4449 - SALSA) and regulation of laboratory developed tests (FDASLA Act of 2022).
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, Hooper, Lundy & Bookman, P.C. lobbied for Roche Diagnostics Corporation , earning $50,000. The report was filed on Oct. 20, 2022.
Original Filing: 301414210.xml
Lobbying Issues
Issues relating to COVID diagnostic testing; H.R. 747/S.1018-Access to TESTs Act; H.R. 3463/S. 1693-Medical Supplies for Pandemics Act of 2021; S.1974-Strengthening America's Strategic National Stockpile Act of 2021; S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, H.R. 7667, the "Food and Drug Amendments of 2022"; H.R. 4128/S. 2209; S. 4348 Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022; The Verifying Accurate Leading-edge IVCT Development Act of 2021; Issues related to public health emergency preparedness.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 4128/S. 2209 The Verifying Accurate Leading-edge IVCT Development Act of 2021.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
S. 3799-PREVENT Pandemics Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S.4449 / HR 8188 Saving Access to Laboratory Services Act (SALSA).
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, Hooper, Lundy & Bookman, P.C. lobbied for Roche Diagnostics Corporation , earning $50,000. The report was filed on July 19, 2022.
Original Filing: 301387620.xml
Lobbying Issues
Issues relating to COVID diagnostic testing; H.R. 747/S.1018-Access to TESTs Act; H.R. 3463/S. 1693-Medical Supplies for Pandemics Act of 2021; S.1974-Strengthening America's Strategic National Stockpile Act of 2021; S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, H.R. 7667, the "Food and Drug Amendments of 2022".
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 4128/S.2209, the Verifying Accurate Leading-edge IVCT Development Act of 2021 (the VALID Act of 2021).
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
S. 3799-PREVENT Pandemics Act.
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, Hooper, Lundy & Bookman, P.C. lobbied for Roche Diagnostics Corporation , earning $50,000. The report was filed on April 20, 2022.
Original Filing: 301364791.xml
Lobbying Issues
Issues relating to COVID diagnostic testing; H.R. 747/S.1018-Access to TESTs Act; H.R. 3463/S. 1693-Medical Supplies for Pandemics Act of 2021; S.1974-Strengthening America's Strategic National Stockpile Act of 2021.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 4128/S.2209, the Verifying Accurate Leading-edge IVCT Development Act of 2021 (the VALID Act of 2021).
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
S. 3799-PREVENT Pandemics Act
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, Hooper, Lundy & Bookman, P.C. lobbied for Roche Diagnostics Corporation , earning $50,000. The report was filed on Jan. 19, 2022.
Original Filing: 301329317.xml
Lobbying Issues
Issues relating to COVID diagnostic testing; H.R. 747 and S.1018-Access to TESTs Act; H.R. 3463 and S. 1693-Medical Supplies for Pandemics Act of 2021; S.1974-Strengthening America's Strategic National Stockpile Act of 2021.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Verifying Accurate Leading-edge IVCT Development (VALID) Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues relating to Medicare clinical laboratory fee schedule payment reductions and data reporting (S.610-Protecting Medicare and American Farmers from Sequester Cuts Act).
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, Hooper, Lundy & Bookman, P.C. lobbied for Roche Diagnostics Corporation , earning $50,000. The report was filed on Oct. 19, 2021.
Original Filing: 301303223.xml
Lobbying Issues
The Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (HR 4128/S 2209); The Access to TESTs Act (HR 747/S1018); The Medical Supplies for Pandemics Act of 2021 (HR 3463/S 1693); The Strengthening Americas Strategic National Stockpile Act of 2021 (S. 1974).
Agencies Lobbied
U.S. Senate
Lobbying Issues
The Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (HR 4128/S 2209).
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare payment for clinical laboratories and diagnostic tests.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, Hooper, Lundy & Bookman, P.C. lobbied for Roche Diagnostics Corporation , earning $50,000. The report was filed on July 20, 2021.
Original Filing: 301284990.xml
Lobbying Issues
Issues related to diagnostic testing; "Access to TESTs Act" (H.R. 747/S. 1018); Issues related to inclusion of diagnostics in the Strategic National Stockpile; "United States Innovation and Competition Act of 2021" (S. 1260) relating to the Strategic National Stockpile; "Medical Supplies for Pandemics Act of 2021" (H.R. 3463/S. 1693).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021" (H.R. 4128/S. 2209).
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2021
In Q1, Hooper, Lundy & Bookman, P.C. lobbied for Roche Diagnostics Corporation , earning $50,000. The report was filed on April 20, 2021.
Original Filing: 301263772.xml
Lobbying Issues
Issues related to diagnostic testing; The Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2020 (HR 6102/S 3404); The Access to TESTs Act (HR 747).
Agencies Lobbied
U.S. Senate
Lobbying Issues
The Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2020 (HR 6102/S 3404).
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare payment for clinical laboratories and diagnostic tests.
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, Hooper, Lundy & Bookman, P.C. lobbied for Roche Diagnostics Corporation , earning $50,000. The report was filed on Jan. 20, 2021.
Original Filing: 301242002.xml
Lobbying Issues
Policies related to diagnostic testing and diagnostic testing capacity; The Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2020 (HR 6102/S 3404); ), Consolidated Appropriations Act, 2021 (H.R. 133).
Agencies Lobbied
U.S. Senate
Lobbying Issues
The Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2020 (HR 6102/S 3404).
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare payment for clinical laboratories and diagnostic tests.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, Hooper, Lundy & Bookman, P.C. lobbied for Roche Diagnostics Corporation , earning $50,000. The report was filed on Oct. 19, 2020.
Original Filing: 301216839.xml
Lobbying Issues
Policies related to diagnostic testing and diagnostic testing capacity; The Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2020 (HR 6102/S 3404).
Agencies Lobbied
U.S. Senate
Lobbying Issues
The Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2020 (H.R. 6102/S. 3404).
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2020
In Q2, Hooper, Lundy & Bookman, P.C. lobbied for Roche Diagnostics Corporation , earning $50,000. The report was filed on July 18, 2020.
Original Filing: 301193380.xml
Lobbying Issues
Families First Coronavirus Response Act (H.R. 6201); Coronavirus Aid, Relief and Economic Security Act, policies related to diagnostic testing capacity (H.R. 748).
Agencies Lobbied
U.S. Senate
Lobbying Issues
The Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2020 (H.R. 6102/S. 3404).
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2020
In Q1, Hooper, Lundy & Bookman, P.C. lobbied for Roche Diagnostics Corporation , earning $50,000. The report was filed on April 20, 2020.
Original Filing: 301177232.xml
Lobbying Issues
Families First Coronavirus Response Act (H.R. 6201); Coronavirus Aid, Relief and Economic Security Act (H.R. 748).
Agencies Lobbied
U.S. Senate
Lobbying Issues
The Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2018 (H.R. 6102/S. 3404).
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2019
In Q4, Hooper, Lundy & Bookman, P.C. lobbied for Roche Diagnostics Corporation , earning $50,000. The report was filed on Jan. 17, 2020.
Original Filing: 301109396.xml
Lobbying Issues
The Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2018 Discussion draft; Laboratory Access for Beneficiaries Act, (H.R. 3584/S. 3049).
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Disease Research/Clinical Labs
3rd Quarter, 2019
In Q3, Hooper, Lundy & Bookman, P.C. lobbied for Roche Diagnostics Corporation , earning $50,000. The report was filed on Oct. 20, 2019.
Original Filing: 301072772.xml
Lobbying Issues
The Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2018 Discussion draft; Laboratory Access for Beneficiaries Act, H.R. 3584
Agencies Lobbied
U.S. Senate
Lobbying Issues
The Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2018 Discussion draft; Laboratory Access for Beneficiaries Act, H.R. 3584.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2019
Hooper, Lundy & Bookman, P.C. amended a lobbying report for representation of Roche Diagnostics Corporation in Q22019 on Oct. 20, 2019.
Original Filing: 301072779.xml
Lobbying Issues
The Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2018 Discussion draft; Laboratory Access for Beneficiaries Act, H.R. 3584
Agencies Lobbied
U.S. Senate
Lobbying Issues
The Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2018 Discussion draft; Laboratory Access for Beneficiaries Act, H.R. 3584.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2019
In Q2, Hooper, Lundy & Bookman, P.C. lobbied for Roche Diagnostics Corporation , earning $30,000. The report was filed on July 19, 2019.
Original Filing: 301052354.xml
Lobbying Issues
The Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2018 Discussion draft; Laboratory Access for Beneficiaries Act, H.R. 3584
Agencies Lobbied
U.S. Senate
Lobbying Issues
The Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2018 Discussion draft; Laboratory Access for Beneficiaries Act, H.R. 3584.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2019
In Q1, Hooper, Lundy & Bookman, P.C. lobbied for Roche Diagnostics Corporation , earning $30,000. The report was filed on April 19, 2019.
Original Filing: 301032021.xml
Lobbying Issues
The Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2018 Discussion draft.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Disease Research/Clinical Labs
4th Quarter, 2018
In Q4, Hooper, Lundy & Bookman, P.C. lobbied for Roche Diagnostics Corporation , earning $30,000. The report was filed on Jan. 22, 2019.
Original Filing: 301016483.xml
Lobbying Issues
S. 2852 - The Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; Diagnostic Accuracy & Innovation Act (DAIA) Discussion Draft; S. 3476 - The PEPFAR Extension Act of 2018.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Diagnostic Accuracy & Innovation Act (DAIA) Discussion Draft; S. 3476 - The PEPFAR Extension Act of 2018.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2018
In Q3, Hooper, Lundy & Bookman, P.C. lobbied for Roche Diagnostics Corporation , earning $50,000. The report was filed on Oct. 19, 2018.
Original Filing: 300992735.xml
Lobbying Issues
S. 2852 - The Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; Diagnostic Accuracy & Innovation Act (DAIA) Discussion Draft; S. 3476 - The PEPFAR Extension Act of 2018.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Diagnostic Accuracy & Innovation Act (DAIA) Discussion Draft; S. 3476 - The PEPFAR Extension Act of 2018.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2018
In Q2, Hooper, Lundy & Bookman, P.C. lobbied for Roche Diagnostics Corporation , earning $50,000. The report was filed on July 18, 2018.
Original Filing: 300968773.xml
Lobbying Issues
S. 2852 - The Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; Diagnostic Accuracy & Innovation Act (DAIA) Discussion Draft
Agencies Lobbied
U.S. Senate
Lobbying Issues
Diagnostic Accuracy & Innovation Act (DAIA) Duiscussion Draft.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2018
In Q1, Hooper, Lundy & Bookman, P.C. lobbied for Roche Diagnostics Corporation , earning $50,000. The report was filed on April 18, 2018.
Original Filing: 300947646.xml
Lobbying Issues
Discussion Draft for a regulatory framework for in-vitro clinical tests (Diagnostic Accuracy & Innovation Act or DAIA); Pandemic All-Hazards Preparedness Reauthorization Act; H.R. 3271 and S.1914 - Protecting Access to Diabetic Testing Supplies Act of 2017 .
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 3271 and S.1914 - Protecting Access to Diabetic Testing Supplies Act of 2017.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1892 - The Bipartisan Budget Act of 2018
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2018
Hooper, Lundy & Bookman, P.C. filed a lobbying registration on Jan. 26, 2018 to represent Roche Diagnostics Corporation, effective Jan. 1, 2018.
Original Filing: 300938642.xml
Issue(s) they said they’d lobby about: H.R. 3271 - Protecting Access to Diabetic Testing Supplies Act of 2017; S. 1914 - Protecting Access to Diabetes Supplies Act of 2017; Yet to be introduced House and Senate proposal for a regulatory framework for in-vitro clinical testing. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...